Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 27, 2025; 17(12): 110931
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.110931
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.110931
De novo arthropathy following glucocorticoid treatment for severe alcohol-associated hepatitis: Five case reports
Queralt Herms, Sonia Torres, Jordi Gratacós-Ginès, Elisa Pose, Liver Unit, Hospital Clínic de Barcelona, Barcelona 08036, Catalonia, Spain
Patrick S Kamath, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, United States
Jordi Gratacós-Ginès, Elisa Pose, Malalties Hepàtiques i Digestives, Institut d’ Investigacions Biomèdiques August Pi i Sunyer, Barcelona 08036, Catalonia, Spain
Jordi Gratacós-Ginès, Elisa Pose, Enfermedades Hepáticas y Digestivas, Centro de Investigación Biomédica En Red de Enfermedades Hepáticas y Digestivas, Madrid 28029, Spain
Elisa Pose, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona 08036, Catalonia, Spain
Co-corresponding authors: Jordi Gratacós-Ginès and Elisa Pose.
Author contributions: Herms Q, Torres S, Gratacós-Ginès J, and Pose E contributed to writing original draft; Gratacós-Ginès J and Pose E contributed equally to this manuscript as co-corresponding authors; All authors participated in the manuscript review and editing. All authors have read and approved the final manuscript.
Supported by the Instituto de Salud Carlos III, No. PI22/00910.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: Dr. Gratacós-Ginès reports that Dr. Pose recieved personal fees from GlaxoSmithKline, during the conduct of the study.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jordi Gratacós-Ginès, MD, PhD, Liver Unit, Hospital Clínic de Barce
Received: June 19, 2025
Revised: July 21, 2025
Accepted: November 17, 2025
Published online: December 27, 2025
Processing time: 190 Days and 20.1 Hours
Revised: July 21, 2025
Accepted: November 17, 2025
Published online: December 27, 2025
Processing time: 190 Days and 20.1 Hours
Core Tip
Core Tip: Despite most adverse events following glucocorticoid (GC) administration for severe alcohol-associated hepatitis (SAH) are well-known, joint symptoms are overlooked and not mentioned in hepatology literature. We report a series of five patients, selected from a prospective cohort of patients with biopsy-proven SAH, who developed joint symptoms following GC cessation. Although the final diagnosis varied among patients, the emergence of joint symptoms after GC therapy for SAH represents a novel and noteworthy observation for clinicians managing these cases. In this report we hypothesize that some patients suffered from GC withdrawal syndrome, and we describe the therapeutic approach used.